Antihypertensive mechanism of the dipeptide Val-Tyr in rat aorta

Peptides

Volumn 29, Issue 2, 2008, Pages 261-267

  Vercruysse, Lieselot ^a   Morel, Nicole ^b   Van Camp, John ^a   Szust, Justyna ^a   Smagghe, Guy ^a  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Antihypertensive mechanism; Organ bath; Rat aorta; Val Tyr

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR; CALCIUM CHANNEL; DIPEPTIDE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; UNCLASSIFIED DRUG; VALYLTYROSINE;

ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR RING;

ACETYLCHOLINE; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICAL SCAVENGERS; LISINOPRIL; MALE; NOREPINEPHRINE; OLIGOPEPTIDES; POTASSIUM CHLORIDE; RATS; RATS, WISTAR; VASOCONSTRICTION;

RATTUS;

EID: 39149104007     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.09.023     Document Type: Article

References (23)

1. Benzie I., and Strain J. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 239 (1996) 70-76
2. Chang B., Chen R., Huang I., and Chang H. Assays for angiotensin converting enzyme inhibitory activity. Anal Biochem 291 (2001) 84-88
3. El-Hilaly J., Lyoussi B., Wibo M., and Morel N. Vasorelaxant effect of the aqueous extract of Ajuga iva in rat aorta. J Ethnopharmacol 93 (2004) 69-74
4. Firuzi O., Lacanna A., Petrucci R., Marrosu G., and Saso L. Evaluation of the antioxidant activity of flavonoids by "ferric reducing antioxidant power" assay and cyclic voltammetry. Biochim Biophys Acta 1721 (2005) 174-184
5. FitzGerald R.J., and Meisel H. Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. Br J Nutr 84 (2000) S33-S37
6. FitzGerald R.J., Murray B., and Walsch D.J. Hypotensive peptides from milk proteins. J Nutr 134 (2004) 980S-988S
7. 2+ and contraction in smooth muscle. Trends Pharmacol Sci 25 (2004) 388-393
8. Kawasaki T., Seki E., Osajima K., Yoshida M., Asada K., Matsui T., et al. Antihypertensive effect of Valyl-Tyrosine, a short chain peptide derived from sardine muscle hydrolyzate, on milk hypertensive subjects. J Hum Hypertens 14 (2000) 519-523
9. Korhonen H., and Pihlanto A. Food-derived bioactive peptides-opportunities for designing future foods. Curr Pharm Des 9 (2003) 1297-1308
10. Matsufuji H., Matsui T., Ohshige S., Kawasaki T., Osajima K., and Osajima Y. Antihypertensive effects of angiotensin fragments in SHR. Biosci Biotechnol Biochem 59 (1995) 1398-1401
11. Matsufuji H., Matsui T., Seki E., Osajima K., Nakashima M., and Osajima Y. Angiotensin I-converting enzyme inhibitory peptides in an alkaline protease hydrolyzate derived from sardine muscle. Biosci Biotechnol Biochem 58 (1994) 2244-2245
12. Matsui T., Hayashi A., Tamaya K., Matsumoto K., Kawasaki T., Murakami K., et al. Depressor effect induced by dipeptide, Val-Tyr, in hypertensive transgenic mice is due, in part, to the suppression of human circulating rennin-angiotensin system. Clin Exp Pharmacol Physiol 30 (2003) 262-265
13. Matsui T., Imamura M., Oka H., Osajima K., Kimoto K., Kawasaki T., et al. Tissue distribution of antihypertensive dipeptide, Val-Tyr, after its single oral administration to spontaneously hypertensive rats. J Pept Sci 10 (2004) 535-545
14. Matsui T., Tamaya K., Seki E., Osajima K., Matsumoto K., and Kawasaki T. Val-Tyr as a natural antihypertensive dipeptide can be absorbed into the human circulatory blood system. Clin Exp Pharmacol Physiol 29 (2002) 204-208
15. 2+ channel inhibition in cultured vascular smooth muscle cells. Hypertens Res 28 (2005) 545-552
16. Saito Y., Wanezaki K., Kawato A., and Imayasu S. Antihypertensive effects of peptide in sake and its by-products on spontaneously hypertensive rats. Biosci Biotechnol Biochem 58 (1994) 812-816
17. Schlesier K., Harwat M., Bohm V., and Bitsch R. Assessment of antioxidant activity by using different in vitro methods. Free Radic Res 36 (2002) 177-187
18. Shimokawa H., Yasutake H., Fujii K., Owada M.K., Nakaike R., Fukumoto Y., et al. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovascular Pharmacol 28 (1996) 703-711
19. Silva J.P., Areias F.M., Proenca F.M., and Coutinho O.P. Oxidative stress protection by newly synthesized nitrogen compounds with pharmacological potential. Life Sci 78 (2006) 1256-1267
20. Valko M., Leibfritz D., Moncol J., Cronin M.T.D., Mazur M., and Telser J. Free radicals and antioxidants in normal physiological functions and human diseases. Int J Biochem Cell Bio 39 (2007) 44-84
21. Vanhoutte P.M., and Mombouli J.V. Vascular endothelium: vasoactive mediators. Prog Cardiovasc Dis 39 (1996) 229-238
22. Vercruysse L., Smagghe G., Herregods G., and Van Camp J. ACE inhibitory activity in enzymatic hydrolysates of insect protein. J Agric Food Chem. 53 (2005) 5207-5211
23. Whelton P.K., He J., and Muntner P. Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia. J Hum Hypertens 18 (2004) 545-551